[Comment] Semaglutide 7·2 mg: another step towards tackling diseases mediated by obesity

In The Lancet Diabetes & Endocrinology, the STEP-UP T2D and STEP-UP trial groups present new findings on the efficacy and safety of higher-dose semaglutide (7·2 mg once weekly) in individuals with obesity, both with and without type 2 diabetes.1,2 These trials build upon the foundational evidence supporting semaglutide 2·4 mg as an effective bodyweight management drug for people with diseases mediated by obesity. The clinical trials of semaglutide, and its main incretin-based alternative tirzepatide, have consistently shown very substantial and well sustained bodyweight loss and major therapeutic benefits across a range of secondary conditions—notably type 2 diabetes, prediabetes, hypertension, sleep apnoea, and heart failure.